Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | HTR6 | P50406 | 4/20 | 0.54 |
| ▸ | NAMPT | P43490 | 2/20 | 0.53 |
| ▸ | GCK | P35557 | 5/20 | 0.51 |
| ▸ | GCKR | Q14397 | 5/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | HTR2A | P28223 | 2/20 | 0.49 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MPO | P05164 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17337 | 0.83 | KDM4E (0.56) | KDM4EHTR6NAMPTGCKGCKR | |
| SCHEMBL4014765 | 0.79 | KDM4E (0.51) | KDM4EHTR6NAMPTGCKGCKR | |
| SCHEMBL18503 | 0.79 | GCK (0.60) | KDM4EGCKGCKR | |
| SCHEMBL10834173 | 0.78 | AGTR1 (0.65) | KDM4EHTR6NAMPTHTR2ALMNA | |
| SCHEMBL30094555 | 0.77 | ALDH1A1 (0.55) | HTR6NAMPTCYP3A4HTR2ALMNA | |
| SCHEMBL15232696 | 0.77 | HTR6 (0.54) | KDM4EHTR6NAMPTHTR2AKCNH2 | |
| SCHEMBL2568189 | 0.77 | ALDH1A1 (0.55) | HTR6NAMPTCYP3A4HTR2ALMNA | |
| SCHEMBL7959283 | 0.77 | HTR2A (0.56) | KDM4EHTR6HTR2ALMNAKCNH2 | |
| SCHEMBL2570550 | 0.77 | KDM4E (0.55) | KDM4EHTR6NAMPTHTR2ALMNA | |
| SCHEMBL15231831 | 0.77 | LOXL2 (0.50) | HTR6NAMPTHTR2AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4536221-A1 | TRIAZOLOPYRIDINE POLYMORPH A | APM THERAPEUTICS 1, INC. (US) | 2025-04-16 | — | — | EP | disclosed |
| WO-2023244539-A1 | TRIAZOLOPYRIDINE POLYMORPH A | APM THERAPEUTICS 1, INC. (US) | 2023-12-21 | — | — | WO | disclosed |
| EP-3204007-B1 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | APM THERAPEUTICS 1 INC (US) | 2023-12-20 | — | — | EP | disclosed |
| US-11746108-B1 | Triazolopyridine polymorph A | APM THERAPEUTICS 1, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-11746108-B1 | Triazolopyridine polymorph A | APM THERAPEUTICS 1, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-11746108-B1 | Triazolopyridine polymorph A | APM THERAPEUTICS 1, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-10472357-B2 | Triazolopyridine compounds and methods for the treatment of cystic fibrosis | FLATLEY DISCOVERY LAB, LLC (US) | 2019-11-12 | — | — | US | disclosed |
| US-10472357-B2 | Triazolopyridine compounds and methods for the treatment of cystic fibrosis | FLATLEY DISCOVERY LAB, LLC (US) | 2019-11-12 | — | — | US | disclosed |
| US-9926315-B2 | Triazolopyridine compounds and methods for the treatment of cystic fibrosis | FLATLEY DISCOVERY LAB, LLC (US) | 2018-03-27 | — | — | US | disclosed |
| US-9926315-B2 | Triazolopyridine compounds and methods for the treatment of cystic fibrosis | FLATLEY DISCOVERY LAB, LLC (US) | 2018-03-27 | — | — | US | disclosed |
| WO-2016057522-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB (US) | 2016-04-14 | — | — | WO | disclosed |
| US-20160096835-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | APM THERAPEUTICS 1, INC. | 2016-04-07 | — | — | US | disclosed |
| US-20160096835-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | APM THERAPEUTICS 1, INC. | 2016-04-07 | — | — | US | disclosed |
| US-20160096835-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | APM THERAPEUTICS 1, INC. | 2016-04-07 | — | — | US | disclosed |
| WO-2014074715-A1 | CYCLOPROPYL AMIDE DERIVATIVES | GENENTECH, INC. (US) | 2014-05-15 | — | — | WO | disclosed |
| US-7696217-B2 | 17-acetamido-4-azasteroid derivatives as androgen receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2010-04-13 | — | — | US | disclosed |
| US-7696217-B2 | 17-acetamido-4-azasteroid derivatives as androgen receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2010-04-13 | — | — | US | disclosed |
| US-4237300-A | CHEMICAL INTERMEDIATES FOR IMIDAZO(1,2-A)PYRIDINE ANTHELMINTIC AGENTS AS WELL AS BEING A FUNGICIDE | MERCK & CO., INC. (US) | 1980-12-02 | — | — | US | disclosed |
| US-4177274-A | ANTHELMINTICS | MERCK & CO., INC. (US) | 1979-12-04 | — | — | US | disclosed |
| US-4096264-A | ANTHELMINTICS | MERCK & CO., INC. (US) | 1978-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10472357-B2 | Triazolopyridine compounds and methods for the treatment of cystic fibrosis | CFTR, KCNJ11, KCNJ1 | KDM4E 4230/4885HTR6 3059/4885NAMPT 1893/4885 |
| US-20160096835-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, KCNJ11, KCNJ1 | KDM4E 4230/4885HTR6 3059/4885NAMPT 1893/4885 |
| US-11746108-B1 | Triazolopyridine polymorph A | CYP3A5, CYP3A4, CYP3A43 | KDM4E 4193/4885HTR6 1261/4885NAMPT 759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.